Metaphore Pharmaceuticals, Inc. Research On M40403 Is Published In September Issue Of Pain 
10/19/2005 5:11:50 PM

FT. LEE, N.J., Oct. 14 /PRNewswire/ -- Metaphore Pharmaceuticals, Inc., an emerging pharmaceutical company developing drugs for the treatment of pain, autoimmune disorders and inflammation, today announced the publication of its research in a leading peer-reviewed publication, PAIN.

The article is entitled "Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartate-mediated hyperalgesia." The article can be found in PAIN, Volume 111, Issues 1-2, September 2004, Pages 96-103.

The research findings describe that superoxide is a key factor in glutamate-induced pain. Overproduction of glutamate is known to play a role in pain resulting from numerous disease states including cancer and neuropathic pain. Metaphore's lead compound, M40403, is a synthetic version of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissue. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.

Metaphore also recently announced research that was published in The Journal of Pharmacology and Experimental Therapeutics (JPET). That paper showed that superoxide is a novel mediator of pain, and that SOD mimetics (SODm) may therefore have an important role in the management of inflammatory pain. The abstracts published in PAIN and JPET were presented at the Neuroscience 2003 conference in New Orleans.

"In the JPET article, it was shown that superoxide is a novel mediator of pain associated with inflammation. The research published in PAIN is promising as it demonstrates yet another role that the enzyme, and Metaphore's lead compound, can play in pain management, namely pain resulting from the overproduction of glutamate," said article Senior Investigator Dr. Daniela Salvemini, Metaphore's Senior Vice President, Research. "These preclinical findings broaden the potential uses of Metaphore's superoxide dismutase mimetics in pain of various etiologies and have provided additional support for our ongoing clinical development program."

Metaphore is currently conducting two Phase II clinical trials of its lead compound, M40403iv. One study is in post-operative pain and the other study is in cancer pain. In April 2004, Metaphore announced positive results from a prior Phase II study demonstrating that the addition of M40403 to morphine (an opioid) improved the pain relieving effects of morphine in every measure of analgesic efficacy, including faster onset, longer duration, greater peak effect, and greater overall effect. The addition of M40403 also increased pain relief without increasing problematic side effects associated with morphine.

According to IMS Health, the total US market for pain management pharmaceuticals, excluding over-the-counter products, was $16.6 billion in 2003. Of this market, the opioid analgesics market was approximately $5.6 billion, representing 75% of analgesics prescriptions in 2003.

About M40403 and SOD Mimetics

Metaphore's lead compound, M40403iv, is a synthetic version of a naturally occurring enzyme produced by the body known as superoxide dismutase (SOD). SOD functions in the body to neutralize free radicals, thereby reducing inflammation, preventing tissue injury and reducing pain. These free radicals, called superoxides, are overproduced in the presence of cell or tissue injury, inflammation and many disease processes. Elevated levels of superoxides can overwhelm the body's natural production of SODs, resulting in a continuing cycle of cell injury, inflammation, and pain. Metaphore has developed SOD mimetics (SODm), which are synthetic compounds that mimic the actions of SODs and supplement the body's natural process of reducing inflammation, limiting cellular damage and relieving pain.

In addition, SODm has the ability to substantially contribute to the pain relieving benefits associated with opioids. In Phase II Clinical Trials, M40403 markedly improved the pain relief produced by opioids while making them more effective and more predictable. In independent tests by the National Institute on Drug Abuse, M40403 was found to have no addictive properties or abuse liability.

More about the Company

Metaphore Pharmaceuticals, Inc. is a privately held, emerging pharmaceutical company which discovers, develops and will market drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise in chemistry and biology to discover and develop small molecule compounds that mimic the activity of human enzymes. Metaphore's lead compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.

Metaphore has a global, multilayered intellectual property estate covering its broad class of compounds including composition of matter and use patents. This IP estate includes 70 issued and 63 pending worldwide patents.

Product candidates in U.S. clinical testing have broad therapeutic potential across a variety of diseases. Metaphore currently focuses its clinical development efforts in pain, rheumatoid arthritis and inflammatory disorders. These markets are significant in terms of scope and size. The company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For more information on Metaphore, please visit the Web site at:

This press release contains forward-looking statements based on information available to Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Metaphore's actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. In addition, we are developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Metaphore disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Daniela Salvemini, Ph.D

Metaphore Pharmaceuticals, Inc.

CONTACT: Alan W. Dunton, M.D., President and Chief Executive Officer,, or Sara E. K. Cooper, Director of CorporateCommunications,, both of Metaphore Pharmaceuticals,+1-201-947-7707; or Scott M. Solomon, Vice President, Sharon MerrillAssociates, Inc., +1-617-542-5300,; or SeanLeous, Vice President, Financial Dynamics, +1-212-850-5755,